SAN FRANCISCO—Ferumoxytol, a novel IV iron replacement drug, may be more effective than oral iron in hemodialysis patients receiving anemia treatment with an erythropoiesis-stimulating agent (ESA), according to study findings presented here at Renal Week 2007.